<DOC>
	<DOCNO>NCT01322594</DOCNO>
	<brief_summary>Phase I study evaluate safety tolerability single ascend intravenous dos MEDI2338 subject stable , mild moderate chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>A Study Evaluate Safety MEDI2338 Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Aged ≥ 40 year time screen . Females nonchildbearing potential define surgically sterile least 2 year postmenopausal . Males , unless surgically sterile , must use 2 highly effective method birth control screen end trial . A diagnosis mild moderate COPD . Cigarette smoke history ≥10 pack year . Ability understand comply protocol requirement , instruction restriction . COPD symptom adequately control therapeutic regimen change 4 week prior screen . Current diagnosis respiratory condition COPD . Active history disease condition would , opinion investigator and/or medical monitor , place subject unacceptable risk participate study . History suspect history alcohol misuse recreational substance abuse . Treatment oral IV corticosteroid within 8 week prior screen . Concurrent enrolment another clinical study . Receipt investigational drug therapy use biologicals within 6 month prior screen . Known history allergy reaction component investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
</DOC>